Navigation Links
Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Date:2/24/2009

AMSTERDAM, the Netherlands, February 24 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year of 2008.

    Highlights

    - Extra clinical trial in LPL deficiency causes a delay of the announced
      filing date for lead product GlyberaTM which is now expected H2 2009
    - Positive clinical data on GlyberaTM
    - CEO Ronald Lorijn resigned for personal reasons
    - Start of clinical multicenter Hemophilia B trial in 2009
    - Start development of treatments for Duchenne Muscular Dystrophy and
      Parkinson's disease
    - Scale up of unique and proprietary production platform to fully support
      worldwide commercial supply for current products
    - Independent supervisory board with three new members bringing extensive
      knowledge and experience.
    - Key financial figures in line with guidance
    - Cash & cash equivalents of EUR 34.2 million at December 31, 2008

Results comparison

AMT's operating loss increased to EUR 18.8 million for 2008, from EUR 14.7 million for 2007. The difference is primarily due to the increase of research & development costs to EUR 13.1 million, from EUR 9.8 million in 2007. This increase is particularly related to the development work on the company's lead product, GlyberaTM, increased staffing for this and other programs and an increase in research collaborations. General and administrative costs increased to EUR 5.9 million, from EUR 5.0 million in 2007, primarily as a result of increased employee costs and increased advisor's fees. The net loss for 2008 was EUR 16.9 million, as compared to a net loss of EUR 14.9 million for 2007. As of December 31, 2008, AMT had cash and cash equivalents of EUR 34.2 million, compared to EUR 51.3 million at December 31, 2007. The cash burn for the year amounted to EURO 17.2 million which i
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Part of Next Biotech Index
3. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
4. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Data on WaferGens SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference
10. Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging
11. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... AtheroNova Inc. (OTCQB: AHRO) today announced that the Company and ... 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy ... Santa Ana division (the "Bankruptcy Court") on ... to be jointly administered. The Company will evaluate ... for all or substantially all of its assets to a ...
(Date:3/3/2015)... Cambridge Semantics, the leading provider of smart ... that it has been named to KMWorld’s 2015 list ... , To create the list each year, KMWorld ... integrators who identify organizations dedicated to the true value ... the right people at the right time. , ...
(Date:3/3/2015)...  Johnson & Johnson Innovation LLC today announced the ... (JLABS @SSF), a 30,000-square foot incubator located at ... Calif. The Johnson & Johnson Innovation, JLABS ... across the healthcare spectrum including biotech, pharmaceutical, medical device, ... resident startups have been selected, including the winners of ...
(Date:3/3/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announced it has initiated commissioning activities for its 30,000 ... Sarnia, Ontario , Canada.  Commissioning ... with the facility being in commercial operation in Q3 ... two months and it is carrying out commissioning and ...
Breaking Biology Technology:AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3
... GmbH and BASF developed pro-t-action(TM) product based on probiotic ... oral careFull research studies introduced at International Association of ... FL , April 1-4 LUDWIGSHAFEN, Germany and ... remedy a main cause of tooth decay affecting an ...
... Board: SNKTY), a Life Sciences company engaged in the ... today announced plans for the creation of a new communication ... updated on key events. Bi-weekly updates will be recorded on ... and running in early May. In addition, callers will be ...
... Neuroscience paper describes role of Zinc in developing Alzheimer,s ... PRAN ) today announced that an independent ... California, Irvine , validates Prana,s fundamental drug strategy for ... and brain metals, such as zinc, that damages synapses ...
Cached Biology Technology:BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 2BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 3BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 4BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 5Senetek PLC Announces New Investor Communication Hotline 2Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients. 2Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients. 3Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients. 4
(Date:2/5/2015)... , Jan. 28, 2015 Research and Markets ... addition of the "Global Biometrics Market (2014-2020): ... and Countries " report to their offering. ... Asia-Pacific is anticipated to overtake ... owing to increasing government spending towards IT security, ...
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition of ... to their offering. , The primary goal ... who she/he is claiming to be, and for this purpose, ... characteristics, such as fingerprint, hand or palm print, iris, face ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... This press release is available in Spanish . ... real headache. U.S. Department of Agriculture (USDA) scientists have identified ... and offer a potential bio-based approach to controlling them. Other ... termite, a nonnative species from Asia, feeds on cellulose from ...
... shown that 30 minutes of daily training provide an equally effective ... have just been published in the American Journal of Physiology ... thirteen weeks, a research team at the Faculty of Medical and ... in their efforts to get into better shape. Half of the ...
... BOSTON, Aug. 22, 2012 Evermedia Group, Inc. (OTC: EVRM) ... 2012 revenue of $703,620, an increase of more than 375% ... all revenue generated in fiscal year 2011 as represented by ... increase in revenue is largely attributable to revenue generated by ...
Cached Biology News:Nematodes with pest-fighting potential identified 230 minutes of daily exercise does the trick 2Evermedia Group Announces 375% Increase in Revenue for Second Quarter 2012 2Evermedia Group Announces 375% Increase in Revenue for Second Quarter 2012 3
Peptide Sequence: ovine COX-1 amino acids 272-282 (LMHYPRGIPPQ) To be used in conjunction with Cayman's COX-1 (ovine) polyclonal antiserum (Catalog No. 160108) to block protein-antibody complex f...
Laminin beta-1/gamma-1 (612C10)...
... choice of Printing Surface (3 glass slides coated with ... 1 silicon wafer coated with 1000 Angstroms of Gold ... PDMS Stamps (3 PDMS micropatterned stamps with series of ... 10 mm or 200 um x 10 mm lines, ...
X box-binding protein 1...
Biology Products: